Ignite Creation Date:
2024-05-06 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 2:15 PM
Study NCT ID:
NCT05074589
Status:
COMPLETED
Last Update Posted:
2023-08-14
First Post:
2021-09-29
Brief Title:
Irinotecan Liposome in Combination With 5-FULV Versus 5-FULV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy |
Keywords: